資源描述：
《management of treatment-naive chronic hcv patients：天真的治療慢性丙型肝炎患者的管理》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在教育資源-天天文庫。
1、AntiviraltreatmentofchronichepatitisCinIVDUsettingsPetrUrbánekDepartmentofInternalMedicine,1stMedicalFacultyCharlesUniversityandCentralMilitaryHospitalPraguepetr.urbanek@uvn.czGoalsofHepatitisCTreatmentPrimaryEradicatethevirusSecondaryPreventprogressiontocirrhosisReduceincid
2、enceofHCCReduceneedfortransplantationEnhancesurvivalDavisGL,etal.JHepatol.1995;22(suppl1):110-114. LindsayKL.Hepatology.1997;26(suppl1):71S-77S.ManagementofHepatitisC: NIHConsensusConferenceStatementAllpatientswithchronichepatitisCarepotentialcandidatesforantiviraltherapyHCV
3、therapyhasbeensuccessfulevenwhenthepatientshavenotabstainedfromcontinueddrugoralcoholuse....Thus,itisrecommendedthattreatmentofactiveinjectiondrugusebeconsideredonacase-by-casebasisandthatactiveinjectiondruguseinandofitselfnotbeusedtoexcludesuchpatientsfromantiviraltherapy.T
4、reatmentisrecommendedforpatientswithanincreasedriskofdevelopingcirrhosisNIHManagementofHepatitisCConsensusConferenceStatement.June10-12,2002.CurrentlyApprovedTreatmentsforHCVTherapyChronicillnessmanagedwithcombinationofInterferonalfa(subcutaneousinjections)Interferonalfa2aa
5、lfa2bconsensusinterferonalfa-1Pegylatedinterferonalfa2aalfa2bRibavirin(tablets)Directlyactingantivirals(tablets)TelaprevirBoceprevirNIHRecommendedHCVTherapiesPeg-IFN+RBVmoreeffectivethanstandardIFN+RBVcombinationorpeg-IFNaloneGenotype1Peg-IFN+RBV1000-1200mg/day→48weeksGeno
6、type2or3Peg-IFN+RBV800mg/day→24weeksGoaloftreatmentisSVRDefinedasNodetectableserumHCVRNA24weeksaftertheend oftreatmentTestedusingsensitiveHCVRNAassaywithlowerlimitofdetectionof50IU/mLNIHManagementofHepatitisCConsensusConferenceStatement.June10-12,2002.NIHConsensusStatementRe
7、commendsTreatingIDUsManagementofHCVisenhancedbylinkingtodrug-treatmentprogramsMethadoneisnotacontraindicationtoHCVtreatmentHCVtreatmentofactiveIDUsshouldbeconsideredonacase-by-casebasisActiveIDUinandofitselfshouldnotexcludesuchpatientsfromantiviraltherapyNIHManagementofHepat
8、itisCConsensusConferenceStatement.June10-12,2002..EvaluationofIDUsforViralH
